2026-09-14 Posted by TideChem view:37
Citric acid is a familiar pharmaceutical excipient, but selecting an appropriate grade involves more than checking chemical purity. Hydration state, pharmacopeial compliance, trace metals, microbial quality, endotoxins, packaging and supplier controls can all affect its suitability for a peptide or oligonucleotide product.
This distinction becomes particularly important in parenteral formulations and lipid nanoparticle manufacturing. A material that meets a general purity specification may still lack the controls required for an injectable peptide or an RNA formulation process.
The right citric acid grade should therefore be selected according to its intended function, route of administration, manufacturing stage and effect on the drug product’s critical quality attributes.
Citric acid is a weak triprotic organic acid with three carboxylic acid groups. Its molecular formula is C6H8O7.
Commercial material is commonly supplied in two forms:
| Form | CAS number | Molecular weight |
| Anhydrous citric acid | 77-92-9 | 192.12 g/mol |
| Citric acid monohydrate | 5949-29-1 | 210.14 g/mol |
Citric acid monohydrate contains one molecule of water for each molecule of citric acid. The theoretical water contribution is approximately 8.6% of the monohydrate’s mass.
Anhydrous and monohydrate material should not be substituted mass-for-mass without recalculating the required quantity. For molar preparation, 192.12 g of anhydrous citric acid and 210.14 g of the monohydrate each represent approximately one mole.
The USP-NF monograph defines citric acid monohydrate as containing 99.5% to 100.5% citric acid when calculated on an anhydrous basis. USP-NF monograph
Citric acid can perform several functions, sometimes within the same process.
Citric acid can lower formulation pH without requiring a separate buffer system. This may improve the solubility or chemical stability of a peptide, conjugate or formulation component.
A pH-adjusting agent does not necessarily provide adequate buffer capacity. The required concentration depends on the expected acid or base load during manufacturing and storage.
Citric acid is normally combined with sodium citrate when a citrate buffer is required. Its three dissociation constants are approximately 3.13, 4.76 and 6.40 at 25°C, giving citrate systems useful buffering behavior across several acidic and near-neutral ranges.
Buffer concentration should be no higher than necessary to maintain the target pH. Excessive buffer capacity can affect osmolality, injection-site tolerability, downstream processing or analytical behavior.
Citrate can bind calcium, iron and other metal ions. This may reduce some metal-catalyzed degradation pathways or prevent unwanted precipitation.
Chelation is not universally protective. Citrate-metal complexes can participate in light-induced oxidation under certain conditions. Research involving iron and pharmaceutical carboxylate buffers found that citrate-iron complexes could produce reactive oxygen species during near-UV and visible-light exposure. PubMed
For oxidation-sensitive peptides, low trace-metal levels and appropriate light-protection studies remain important even when citrate is used.
Citric acid may be used during process development to adjust supersaturation, form a citrate salt or change the ionic environment during isolation.
This application is molecule-specific. Citrate can alter solid form, residual solvent removal, hygroscopicity and dissolution behavior. A citrate salt should be characterized as a distinct material rather than treated as a simple pH adjustment.
Citric acid has been used in approved oral and injectable products. Its presence in the FDA Inactive Ingredient Database can support formulation development, but prior use should be evaluated by route, dosage form and exposure.
The database does not establish that every concentration or route is automatically acceptable. FDA guidance explains both the value and limitations of using inactive-ingredient data. FDA Inactive Ingredient Database guidance
Technical-grade citric acid may be suitable for cleaning, industrial processing or non-pharmaceutical development work. Specifications may emphasize assay and general appearance while providing limited control of trace metals, microbial content or pharmaceutical supply-chain documentation.
It should not be assumed suitable for drug-product manufacturing.
Food Chemicals Codex material is intended for food and related applications. It may offer well-defined identity and purity requirements, but these do not automatically address all pharmaceutical expectations.
FCC grade can be appropriate for certain early studies or oral products after risk assessment. Parenteral and clinical applications normally require additional qualification.
Reagent-grade citric acid is designed for laboratory analysis and solution preparation. It may provide high chemical purity but lack pharmaceutical change control, traceable excipient manufacturing or documentation supporting use in a drug product.
High reagent purity and pharmaceutical suitability are different concepts.
Pharmacopeial material is tested against a recognized monograph such as:
Multi-compendial material may simplify global development, but developers should compare the current monographs rather than assume that every test and acceptance criterion is fully harmonized.
Pharmacopeial compliance establishes a useful baseline. It does not eliminate the need for formulation-specific testing. USP General Chapter <1059> notes that excipient properties affecting drug-product performance may not be covered by the monograph and may vary between suppliers or lots. USP excipient performance guidance
“Parenteral grade” is not a substitute for a complete specification. For injectable formulations, additional controls may be required for:
The USP harmonization history specifically distinguishes material that must undergo further processing to ensure acceptable endotoxin levels from material labeled as sterile. USP harmonization document
Both forms can provide the same citrate species after complete dissolution, but they differ in handling and calculation.
Choose based on:
Anhydrous citric acid may be preferred when minimizing introduced water is important. Monohydrate may offer established handling behavior and broad availability.
For an aqueous formulation, the hydration state often has little effect after correct molar adjustment. For lyophilized products, nonaqueous processes or direct dry blending, the difference can become more relevant.
The material form must be clearly identified in the formulation record, batch calculation and certificate of analysis.
Peptide stability is often strongly dependent on pH. Citrate may help maintain an acidic environment that limits deamidation, aggregation or other degradation pathways.
However, lowering pH can introduce different risks:
Buffer selection should therefore be based on comparative stability studies rather than the assumption that citrate is generally better than acetate, histidine, phosphate or another system.
A peptide formulation study should evaluate:
The selected citrate concentration should maintain pH throughout the product’s shelf life without introducing unnecessary ionic strength or osmolality.
PEG conjugation changes molecular size, hydration and chromatographic behavior. The stability of a PEG-peptide conjugate may depend on both the peptide and the chemical bond connecting the PEG chain.
When evaluating citrate, developers should consider:
A buffer that protects the peptide backbone may accelerate cleavage of a pH-sensitive linker. Both components of the conjugate must therefore be monitored.
Citric acid and sodium citrate are commonly used in acidic aqueous phases during lipid nanoparticle preparation.
At acidic pH, ionizable lipids become protonated and interact more effectively with negatively charged oligonucleotides. Published siRNA and mRNA LNP methods frequently use citrate systems around pH 3 to 5, followed by dialysis or tangential-flow filtration into a more suitable storage buffer.
For example, one published LNP study dissolved siRNA in 50 mM sodium citrate at pH 5 before mixing and subsequent buffer exchange. LNP buffer study
Relevant citric acid attributes may include:
The low-pH citrate phase used during particle formation may not be the final product buffer. Developers should distinguish between a process excipient and a finished-product excipient.
Residual citrate after buffer exchange may still affect pH, osmolality, particle surface properties and analytical measurements. Its removal should be demonstrated where it is a critical process parameter.
Particle size is not usually a critical performance attribute once citric acid has fully dissolved. It can still affect manufacturing when citric acid is:
A finer powder may dissolve faster but can generate dust, absorb moisture more readily or show poor flow. Coarser crystals may handle well but dissolve more slowly.
Custom particle-size limits should only be specified when development data show that they affect process performance or finished-product quality.
A citric acid certificate of analysis should be assessed against the intended application rather than accepted solely because it states “pharmaceutical grade.”
Potential attributes include:
| Attribute | Why it matters |
| Identification | Confirms chemical identity and material form |
| Assay | Supports accurate buffer and formulation calculations |
| Water | Distinguishes hydration state and affects weighing |
| Appearance and solution clarity | Detects contamination or insoluble material |
| Related organic acids | May affect purity and buffering behavior |
| Oxalate | Relevant compendial impurity |
| Sulfates and ash | Indicate inorganic contamination |
| Aluminum and other metals | May affect sensitive products |
| Elemental impurities | Supports route-specific risk assessment |
| Endotoxins | Critical for many parenteral processes |
| Bioburden | Supports microbial control |
| Particle size | Relevant where dissolution or powder flow is critical |
| Residual solvents | May be required by the manufacturing route |
| Nuclease control | May be relevant for oligonucleotide processing |
Not every attribute requires routine release testing. Some may be controlled through supplier qualification, process validation or periodic monitoring.
A lipidated GLP-1 analogue shows reduced chemical degradation at pH 4.5 but begins to self-associate at higher citrate concentrations.
The development team compares citrate with acetate and histidine, measuring related substances, aggregation, receptor potency and subvisible particles. A lower citrate concentration provides sufficient pH control while reducing ionic-strength effects.
The lesson is that buffer identity and buffer concentration must be optimized separately.
A PEG-conjugated peptide remains stable in citrate solution, but its cleavable linker hydrolyzes during accelerated storage.
The team adjusts the pH, compares anhydrous and monohydrate calculations, and evaluates residual moisture after lyophilization. Stability is assessed using methods that separately quantify intact conjugate, free peptide and linker-related products.
The lesson is that peptide stability alone does not establish conjugate stability.
An siRNA process uses citrate at acidic pH during rapid lipid mixing. Lot-to-lot variation in particle size appears after scale-up.
The investigation evaluates citrate concentration, pH accuracy, water quality, mixing conditions, RNA concentration and buffer-exchange efficiency. Citric acid purity is confirmed, but the main source of variation is the interaction between flow rate and aqueous-to-ethanol ratio.
The lesson is that excipient quality is important, but it must be evaluated within the complete process.
Citric acid is widely available, but pharmaceutical supply requires more than commercial availability.
Supplier assessment should address:
USP guidance on bulk excipient distribution highlights the risks created by inadequate packaging, repackaging, labeling, storage and transport controls. USP <1197>
Single-use or smaller packaging can reduce repeated opening and moisture exposure during development. Commercial manufacturing may require larger containers or controlled dispensing systems. Packaging configuration should follow actual use patterns.
Tide Chem’s public information documents capabilities in peptide raw materials, PEG derivatives, phosphoramidites and small nucleic acid drug materials, together with custom development and CDMO support. These capabilities can be relevant when citrate-buffered processes also require non-natural amino acids, PEG linkers, peptide side chains or oligonucleotide building blocks. Tide Chem About Us
For citric acid itself, developers should request and verify a current product-specific package covering:
These capabilities should not be assumed from company-level quality statements. They must be confirmed through the current specification, certificate of analysis and supplier-quality documentation.
Tide Chem states that it maintains QC and QA functions, an ICH-aligned laboratory quality framework and ISO 9001 certification. Product-specific qualification remains necessary for each formulation and development stage. Tide Chem Quality Assurance
It may be suitable for some early research or oral formulations after risk assessment. It should not automatically be used for clinical or parenteral manufacturing.
No. Pharmacopeial compliance does not automatically mean that the material is sterile or has sufficiently low endotoxin for every injectable application.
Not generally. The correct choice depends on formulation calculations, water control, handling and supplier qualification.
Citrate can chelate certain metals, but it does not guarantee protection from oxidation. Citrate-metal complexes may promote photochemical oxidation under some conditions.
Acidic citrate conditions help protonate ionizable lipids during complexation with negatively charged RNA. The formulation is commonly exchanged into another buffer after particle formation.
Technical grade normally lacks the pharmaceutical specifications and supply-chain controls expected for drug-product manufacturing.
No. Assay does not establish endotoxin level, microbial quality, trace-metal content, hydration state or pharmaceutical supply-chain suitability.
Choosing citric acid for peptide and oligonucleotide formulations requires a use-specific assessment. Chemical purity is only one part of the decision.
Developers should first define whether citric acid will act as a pH adjuster, buffer component, chelator, crystallization aid or process excipient. They should then select the appropriate hydration state, pharmacopeial status and additional controls for the dosage form and route of administration.
For peptide and PEG-conjugate formulations, citrate should be evaluated for its effects on solubility, aggregation, oxidation and linker stability. For oligonucleotide LNP processes, pH accuracy, nuclease risk, trace metals and buffer-exchange performance may be particularly important.
A pharmacopeial monograph establishes a baseline, not a complete formulation specification. The final control strategy should connect citric acid’s material attributes with the drug product’s critical quality attributes and manufacturing process.